- Recce Pharmaceuticals’ (ASX:RCE) flagship product is a versatile drug called R327
- It can be used as a gel to treat wound infections
- The company is investigating on patients with Diabetes suffering post-surgery complications
- Shares last traded at 44.5 cents
Recce Pharmaceuticals’ (ASX:RCE) work in the diabetic post-surgery space is set to expand with a key trial in this area being given further safety approvals to expand.
An independent committee has awarded Recce the rights to move onto a phase I/II clinical trial.
The company flagged its plans to expand back in January.
Patients will be treated with R327 “either daily or every second day for 14 days”. Those patients will be housed at the NSW-based Liverpool Hospital.
“All parties involved have agreed to a broadening of patient description and stage of diabetic foot ulcer infection to award greater patient access,” Recce today wrote.
Previously, RCE had been focusing on those suffering complications following amputation in particular, a common outcome for diabetes patients.
That surgery is also not particularly rare in the Australian medical landscape – and especially not the USA’s.
“We look forward to seeing the potential of R327 utilised as a treatment option in patients suffering from DFIs, offering a chance at a better quality of life without the devastating consequences of amputation,” Recce CEO James Graham said.
Shares last traded at 44.5 cents.